Kiora Pharmaceuticals Gains Approval for Phase 2 Trial
In This Article:
Kiora Pharmaceuticals ( (KPRX) ) has issued an update.
Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial of KIO-301 for treating retinitis pigmentosa, aiming to restore vision in patients with severe vision loss. The ABACUS-2 trial will assess the drug’s safety and efficacy across multiple centers in Australia, utilizing a unique photoswitch mechanism that could work for various gene mutations associated with retinal diseases. This innovative approach, supported by Théa Open Innovation, offers hope for a breakthrough in treating inherited retinal conditions.
Find detailed analytics on KPRX stock on TipRanks’ Stock Analysis page.
Terms and Privacy Policy